NewAmsterdam Pharma (NAMS) Revenue (2023 - 2025)
Historic Revenue for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $348000.0.
- NewAmsterdam Pharma's Revenue fell 9880.46% to $348000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 490.86%. This contributed to the annual value of $45.6 million for FY2024, which is 22337.12% up from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's Revenue is $348000.0, which was down 9880.46% from $19.1 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Revenue high stood at $29.1 million for Q3 2024, and its period low was $348000.0 during Q3 2025.
- For the 3-year period, NewAmsterdam Pharma's Revenue averaged around $7.5 million, with its median value being $2.9 million (2023).
- Its Revenue has fluctuated over the past 5 years, first soared by 149053.55% in 2024, then plummeted by 9880.46% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Revenue stood at $803000.0 in 2023, then skyrocketed by 1490.54% to $12.8 million in 2024, then tumbled by 97.28% to $348000.0 in 2025.
- Its Revenue was $348000.0 in Q3 2025, compared to $19.1 million in Q2 2025 and $3.0 million in Q1 2025.